CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

SPECT and PET in ischemic heart failure Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure Modifiable lifestyle factors and heart failure: A Mendelian randomization study Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Heart Failure and Atrial Fibrillation, Like Fire and Fury Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure Dilated cardiomyopathy: so many cardiomyopathies! Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry

Original Research2019 May;21(5):665-675.

JOURNAL:Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF